This study aims to evaluate the short-term outcomes and prognosis and the cardiac safety of pegylated liposomal doxorubicin (PLD)-based neoadjuvant chemotherapy (NAC) compared with epirubicin-based therapy in breast cancer treatment.
Methods:
In total, 304 patients diagnosed with stages II and III breast cancer were enrolled that included 97 cases treated with PLD and 207 controls treated with epirubicin in NAC. The effectiveness of the antibreast cancer treatment was evaluated using overall survival (OS) and disease-free survival (DFS) metrics, whereas cardiac toxicity was measured through the left ventricular ejection fraction (LVEF) and electrocardiogram (ECG) assessments.
Results:
The 5-year DFS and OS rates in the PLD group were 84.5% and 88.7% (with 15 recurrences and 11 deaths), respectively, whereas in the control group, these rates were 72.9% and 79.2% (with 56 recurrences and 43 deaths). Regarding cardiac toxicity, there was no significant difference in ECG abnormalities or LVEF decline between the two groups.
Conclusions:
The study suggests that PLD-based NAC may provide substantial benefits in terms of DFS and OS, along with a safe cardiac toxicity profile, in patients with stage II–III breast cancer.
RastogiP, AndersonSJ, BearHD, et al.Preoperative chemotherapy: Updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. J Clin Oncol, 2008; 26(5):778–785; doi: 10.1200/jco.2007.15.0235
2.
HortobágyiGN, BuzdarAU. Present status of anthracyclines in the adjuvant treatment of breast cancer. Drugs, 1993; 45:10–19; doi: 10.2165/00003495-199300452-00004
3.
LowenthalEA, CarpenterJT. The use of anthracyclines in the adjuvant treatment of breast cancer. Cancer Treat Rev, 1995; 21(3):199–214; doi: 10.1016/0305-7372(95)90001-2
4.
DalyMB, PalT, BerryMP, et al.Genetic/familial high-risk assessment: Breast, ovarian, and pancreatic, version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 2021; 19(1):77–102.
5.
GabizonA, ShmeedaH, GrenaderT. Pharmacological basis of pegylated liposomal doxorubicin: Impact on cancer therapy. Eur J Pharm Sci, 2012; 45(4):388–398; doi: 10.1016/j.ejps.2011.09.006
6.
GabizonAA, LyassO, BerryGJ, et al.Cardiac safety of pegylated liposomal doxorubicin (Doxil/Caelyx) demonstrated by endomyocardial biopsy in patients with advanced malignancies. Cancer Invest, 2004; 22(5):663–669; doi: 10.1081/cnv-200032899
7.
GabizonA, ShmeedaH, BarenholzY. Pharmacokinetics of pegylated liposomal Doxorubicin: Review of animal and human studies. Clin Pharmacokinet, 2003; 42(5):419–436; doi: 10.2165/00003088-200342050-00002
8.
GabizonAA, PatilY, La-BeckNM. New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy. Drug Resist Updat, 2016; 29:90–106; doi: 10.1016/j.drup.2016.10.003
9.
ChengM, SongZ, QiY, et al.A dose-escalating pilot study (NCT03017404) of pegylated liposomal doxorubicin and cyclophosphamide, followed by docetaxel administration as a neoadjuvant chemotherapy regimen in patients with locally advanced breast cancer. Oncol Res Treat, 2019; 42(5):269–274; doi: 10.1159/000498993.
10.
LiR, TianF, QiY, et al.Pegylated liposomal doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy in locally advanced breast cancer (registration number: ChiCTR1900023052). Sci Rep, 2019; 9(1):18135; doi: 10.1038/s41598-019-54387-5
11.
Gil-GilMJ, BelletM, MoralesS, et al.Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: Results of the phase II CAPRICE study. Breast Cancer Res Treat, 2015; 151(3):597–606; doi: 10.1007/s10549-015-3415-2
12.
KuererHM, NewmanLA, SmithTL, et al.Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol, 1999; 17(2):460–469; doi: 10.1200/JCO.1999.17.2.460
13.
KaufmannM, von MinckwitzG, MamounasEP, et al.Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol, 2012; 19(5):1508–1516; doi: 10.1245/s10434-011-2108-2
14.
BaschE, DealAM, DueckAC, et al.Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA, 2017; 318(2):197–198; doi: 10.1001/jama.2017.7156
15.
BurzykowskiT, BuyseM, Piccart-GebhartMJ, et al.Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol, 2008; 26(12):1987–1992; doi: 10.1200/JCO.2007.10.8407
16.
HungCC, YangY, TsaiI, et al.The efficacy of pegylated liposomal doxorubicin-based neoadjuvant chemotherapy in breast cancer: A retrospective case-control study in Taiwan. Biochem Res Int, 2020; 2020:5729389; doi: 10.1155/2020/5729389
17.
Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature, 2012; 490(7418):61–70; doi: 10.1038/nature11412
18.
TuxenMK, ColdS, TangeUB, et al.Phase II study of neoadjuvant pegylated liposomal doxorubicin and cyclophosphamide ± trastuzumab followed by docetaxel in locally advanced breast cancer. Acta Oncol, 2014; 53(10):1440–1445; doi: 10.3109/0284186X.2014.921727
19.
ArtioliG, MocellinS, BorgatoL, et al.Phase II study of neoadjuvant gemcitabine, pegylated liposomal doxorubicin, and docetaxel in locally advanced breast cancer. Anticancer Res, 2010; 30(9):3817–3821.
20.
RossiD, BaldelliAM, CasadeiV, et al.Neoadjuvant chemotherapy with low dose of pegylated liposomal doxorubicin plus weekly paclitaxel in operable and locally advanced breast cancer. Anticancer Drugs, 2008; 19(7):733–737; doi: 10.1097/CAD.0b013e3283043585
21.
SinghJC, MamtaniA, BarrioA, et al.Pathologic complete response with neoadjuvant doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab and pertuzumab in patients with HER2-positive early stage breast cancer: A single center experience. Oncologist, 2017; 22(2):139–143; doi: 10.1634/theoncologist.2016-0268
22.
GogasH, PapadimitriouC, KalofonosHP, et al.Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx) and paclitaxel in locally advanced breast cancer: A phase II study by the Hellenic Cooperative Oncology Group. Ann Oncol, 2002; 13(11):1737–1742; doi: 10.1093/annonc/mdf284
23.
ParkJH, AndersonWF, GailMH. Improvements in US breast cancer survival and proportion explained by tumor size and estrogen-receptor status. J Clin Oncol, 2015; 33(26):2870–2876; doi: 10.1200/JCO.2014.59.9191
24.
LaiJ, PanZ, ChenP, et al.Development and validation of a nomogram incorporating axillary lymph node ratio to predict survival in node-positive breast cancer patients after neoadjuvant chemotherapy. Jpn J Clin Oncol, 2019; 49(1):22–28; doi: 10.1093/jjco/hyy181
25.
BiswasT, JindalC, FitzgeraldTL, et al.Pathologic complete response (pCR) and survival of women with inflammatory breast cancer (IBC): An analysis based on biologic subtypes and demographic characteristics. Int J Environ Res Public Health, 2019; 16(1):124; doi: 10.3390/ijerph16010124
26.
BiswasT, EfirdJT, PrasadS, et al.The survival benefit of neoadjuvant chemotherapy and pCR among patients with advanced stage triple negative breast cancer. Oncotarget, 2017; 8(68):112712–112719; doi: 10.18632/oncotarget.22521
27.
MaoZ, ShenK, ZhuL, et al.Comparisons of cardiotoxicity and efficacy of anthracycline-based therapies in breast cancer: A network meta-analysis of randomized clinical trials. Oncol Res Treat, 2019; 42(7–8):405–413; doi: 10.1159/000500204
28.
RauKM, LinYC, ChenYY, et al.Pegylated liposomal doxorubicin (Lipo-Dox) combined with cyclophosphamide and 5-fluorouracil is effective and safe as salvage chemotherapy in taxane-treated metastatic breast cancer: An open-label, multi-center, non-comparative phase II study. BMC Cancer, 2015; 15:423; doi: 10.1186/s12885-015-1433-4
